Addressing the universal desire to heal

Addressing the universal desire to heal

At Numinus, we believe the societal costs of mental illness, addictions, trauma, and unmet human potential are much too high.

New approaches, new treatments, and new ways of thinking are required — solutions where the world of health care and technology collide — to help individuals and communities heal, discover meaning, and make deeper connections.

We are in this for the long run and the right reasons. We are advancing psychedelic laboratory testing, therapy, and research and hope to create a lifelong relationship between Numinus and our clients in their journey to heal and be well.

Licensed by Health Canada to produce and extract psilocybin from mushrooms

Numinus is at the forefront of addressing the growing prevalence of mental health issues and desire for greater wellness.

Numinus has received Health Canada approval to amend the Company’s existing licence under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind.

With this regulatory approval, Numinus is able to proceed with the production of naturally sourced, sustainable psilocybin for research purposes that will support the emerging field of psychedelic assisted therapy and research, at lower costs to currently produced synthetic psilocybin. The licence also allows Numinus to develop and licence its own exclusive IP for further product development in partnership with leading research organizations — something the research community has been seeking to secure.

The company’s existing licence (in alignment with licence holder Salvation Botanicals Ltd) allows Numinus to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT, and mescaline.

Numinus is dedicated to providing access to therapies that enhance and supplement existing options. Psychedelics will be part of this but will only be available for treatment once approved by regulators and governing bodies.

Transformative change is needed

$51B

Estimated annual economic burden of mental illness in Canada

1 in 2

The number of Canadians who will be affected by mental health issues by the age of 40

4,000

The number of Canadians who die by suicide per year – almost 11 suicides per day

9%+

Percentage of Canadian adults who will suffer PTSD in their lifetime

500,000

Number of unemployed Canadians who are unable to work due to mental health problems

1 in 5

The number of Canadians who suffer from addiction in any given year

50%

Percentage of Canadians experiencing a major depressive episode that do not receive “potentially adequate care”

#4

Canada’s rank in the use of antidepressant drugs per capita. The use of antidepressants is on the rise globally.

Investors